Hypothermia With Intrajugular Cooling in Acute Ischemic Stroke Thrombectomy
- Conditions
- Acute Ischemic Stroke
- Interventions
- Procedure: Hypothermia with intrajugular cooling
- Registration Number
- NCT05488392
- Lead Sponsor
- Capital Medical University
- Brief Summary
Hypothermia with intrajugular cooling is a neuroprotective strategy that has been proven to minimize brain damage and maximize functional preservation in animal models of stroke. The purpose of this proof-of-concept study is to determine the safety and tolerability of intrajugular cooling in patients with acute ischemic stroke who are treated with mechanical thrombectomy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 15
- Age 18-80 years;
- Acute ischemic stroke caused by unilateral internal carotid artery terminal segment/middle cerebral artery M1 segment occlusion;
- In line with the indications for mechanical thrombectomy without contraindications;
- Successful recanalization (mTICI 2b/3) after mechanical thrombectomy that confirmed by digital subtraction angiography;
- Written informed consent provided by the patients or their legal relatives.
- Suffering from cerebral venous system diseases such as cerebral venous thrombosis/stenosis/dysplasia;
- Suffering from heart diseases such as ventricular arrhythmia/myocardial infarction/congestive heart failure;
- Imaging examination after mechanical thrombectomy shows intracranial hemorrhage/contrast extravasation;
- Difficulty in reaching the designated position of the device used for intrajugular cooling;
- Difficulty in complying with intrajugular cooling or other conditions that the investigator considered inappropriate for inclusion.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Intrajugular cooling group Hypothermia with intrajugular cooling The safety and tolerability of hypothermia with intrajugular cooling will be investigated using 3+3 dose-escalation trial design.
- Primary Outcome Measures
Name Time Method Number of participants with major response Within 24 hours after hypothermia with intrajugular cooling Major response is any of the following:
1. Cerebral venous system damage;
2. Cerebral venous thrombosis;
3. Huge hematoma at the puncture site requiring surgical intervention;
4. Malignant arrhythmia within 24 hours;
5. Cardiac arrest within 24 hours;
6. Myocardial infarction within 24 hours;
7. Congestive heart failure within 24 hours.
In the 3 + 3 design, 3 subjects are recruited for a given intrajugular cooling dose level. The trial is stopped if ≥ 2 of 3 subjects at a given dose level show major response. If only 1 of 3 subjects shows major response, 3 more subjects are recruited at a given dose level and a major response in any of them will stop the trial. Otherwise, same procedure is followed for the next dose level. Maximum tolerable dose will be the dose at the level before stopping of the trial. The schedule of advancing duration is 10 min, 15 min, 20 min, 25 min, and 30 min.
- Secondary Outcome Measures
Name Time Method